Regulation2026-04-01

Navigating FDA Guidance for AI in Healthcare

When developing AI for healthcare, regulatory considerations are best introduced early. They are not a separate phase, but part of the overall structure of a project. Frameworks such as the FDA in the United States and the Medical Device Regulation (MDR) in Europe define how systems are evaluated before clinical use.

Among these, the FDA is often used as a reference point, as it provides access to the U.S. market, one of the largest for medical technologies. For many teams, this shapes both validation strategy and documentation from the beginning.

Engaging with regulation early helps align development with expected evidence, reducing gaps between technical work and clinical deployment.

1. FDA framework and risk-based approach

AI systems intended for diagnosis, treatment, or patient management are generally classified as Software as a Medical Device (SaMD). This classification depends on the intended use rather than the underlying technology.

Once under this scope, evaluation follows a risk-based approach. Requirements vary according to how the system is used and the context in which it operates. Several factors contribute to this assessment:

the role of the software (informing vs. driving decisions)
the clinical context (non-serious vs. serious conditions)
the impact on patient care
the possibility for human oversight

Together, these elements determine the level of regulatory scrutiny. In practice, higher risk requires stronger evidence and more extensive review.

This approach is aligned with international frameworks and standards commonly used across regions, such as:

ISO 14971 for risk management
IEC 62304 for software lifecycle processes
ISO 13485 for quality management systems

These standards provide a shared structure that supports both FDA and MDR expectations.

2. Classification and regulatory pathways

Risk classification directly informs the regulatory pathway. The FDA defines three main routes:

510(k): for systems similar to existing devices
De Novo: for novel systems with moderate risk
PMA (Premarket Approval): for high-risk systems

Each pathway implies different expectations in terms of validation, documentation, and clinical evidence.

Because of this, regulatory strategy and development choices are closely connected. Selecting a pathway early helps define the type of data to collect, the structure of evaluation, and the level of evidence required.

3. Documentation and submission

Regulatory submission is based on structured and traceable documentation that connects all stages of development. Rather than a single document, it is a collection of artifacts built progressively.

Core elements typically include:

Intended Use Statement (function, users, context)
Software Requirements Specification (SRS)
Software Design Description (SDD)
Verification & Validation (V&V) Plan and Report
Risk Management File (aligned with ISO 14971)
Data documentation (sources, preprocessing, representativeness)
Clinical evaluation or performance report
Software lifecycle and versioning information

FDA guidance documents and templates provide a structure for organizing these elements, including:

guidance on Software in Medical Devices
Clinical Decision Support (CDS) guidance
Good Machine Learning Practice (GMLP) principles
IMDRF documents on SaMD clinical evaluation

Beyond compliance, submission serves to formalize how the system is used and demonstrate that it performs as expected. It also supports trust among clinicians and institutions. Without clearance, clinical deployment in the U.S. remains limited.

4. Evaluation and AI-specific considerations

The level of evaluation required depends on the selected pathway, but generally includes a combination of technical validation, external testing, and, in some cases, clinical evidence.

AI systems introduce additional dimensions that need to be addressed explicitly. These include:

model evolution, particularly how updates are controlled over time
transparency, including communication of outputs and limitations
data diversity, ensuring consistent performance across populations and settings

These aspects are increasingly reflected in FDA guidance and Good Machine Learning Practice recommendations.

From a practical perspective, this also affects how development is organized. Teams often need to:

track datasets and versions over time
maintain links between data, models, and evaluation results
document model changes and their impact
integrate robustness and external validation early

Incorporating these elements during development helps maintain consistency between model design and regulatory expectations.

5. Personal perspective

In practice, regulatory work is more effective when treated as part of the development process rather than a final requirement. This involves continuously tracking datasets, models, and evaluations, while integrating risk management from early stages.

Planning for external validation early and documenting decisions as they are made reduces later effort and improves coordination between engineering and regulatory teams. It also clarifies interactions with quality and regulatory roles, which typically:

contribute early to classification and intended use
support validation and risk structuring during development
lead documentation and submission in later stages

FDA guidance can be approached as a framework that links development, evaluation, and deployment. Aligning with it progressively helps maintain consistency and supports a smoother transition toward clinical use and market access.